CTMX · CytomX Therapeutics, Inc.
$3.36
+0.01 (+0.30%)
At close · Aug 14
Market Cap
$732.14M
Shares
217.90M
CytomX Therapeutics, Inc. Earnings Call Transcripts
Every quarterly earnings call for CytomX Therapeutics, Inc. (CTMX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼36.6%
$11.15M
−$29.06M
'22 Q3
22-11-08
▲80.8%
$20.12M
−$8.78M
'22 Q4
23-03-27
▲159.9%
$23.50M
−$3.31M
'23 Q1
23-05-09
▲92.4%
$24.72M
−$1.09M
'23 Q2
23-08-08
▲136.7%
$26.38M
$2.99M
'23 Q3
23-11-07
▲32.2%
$26.61M
$837,000
'23 Q4
24-03-11
▲76.4%
$41.46M
$13.79M
'24 Q1
24-05-08
▲1.6%
$25.11M
−$6.53M
'24 Q2
24-08-08
▲26.7%
$33.43M
$5.74M
'24 Q3
24-11-07
▲43.2%
$38.09M
$18.88M
'24 Q4
25-03-06
▲22.8%
$50.92M
$23.52M
'25 Q1
25-05-12
▼25.7%
$18.66M
−$154,000
'25 Q2
25-08-07
▼82.2%
$5.96M
−$14.23M
'25 Q3
25-11-06
▼98.3%
$663,000
−$26.51M
'25 Q4
26-03-16
▼79.9%
$10.26M
−$18.25M
'26 Q1
26-05-07
LATEST
▼92.4%
$1.42M
−$20.67M
'26 Q2
26-08-06
Earnings call
FY26 · Q2
2026-08-06
CytomX Therapeutics, Inc. Q2 FY2026 Earnings Call
Confident tone
Varsetta M monotherapy in late-line CRC
Pan-tumor / GI expansion cohorts
Registrational study planning and timelines
Revenue
$1.42M
▼ 92.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-10
Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-04
Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
CytomX Therapeutics, Inc. Q1 FY2026 Earnings Call
Confident tone
Varsetta M (VarsettaM) in colorectal cancer
Dose optimization and registrational path
EPCAM targeting and ProBody platform
Revenue
$10.26M
▼ 79.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-16
CytomX Therapeutics, Inc. Q4 FY2025 Earnings Call
Confident tone
Varsetta Phase 1 dose expansion efficacy in CRC
Dose optimization cohorts (8.6 / 10 mg/kg, AIBW dosing)
EPCAM ProBody platform and Mazatecan payload
Revenue
$663,000*
▼ 98.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
CytomX Therapeutics, Inc. Q3 FY2025 Earnings Call
Confident tone
CX-2051 Phase I data and progress in colorectal cancer
PROBODY platform and EpCAM targeting
CX-801 masked interferon alpha-2b in melanoma
Revenue
$5.96M
▼ 82.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
CytomX Therapeutics, Inc. Q2 FY2025 Earnings Call
Confident tone
CX2051 in colorectal cancer
CX801 / Keytruda combination in melanoma
Safety and tolerability, especially diarrhea
Revenue
$18.66M
▼ 25.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
CytomX Therapeutics, Inc. Q1 FY2025 Earnings Call
Revenue
$50.92M
▲ 22.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-06
CytomX Therapeutics, Inc. Q4 FY2024 Earnings Call
Positive tone
CX-2051 lead EPCAM ADC in colorectal cancer
CX-801 masked interferon alpha program
Unmet need and bar for activity in late-line CRC
Revenue
$38.09M*
▲ 43.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
CytomX Therapeutics, Inc. Q3 FY2024 Earnings Call
Revenue
$33.43M
▲ 26.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
CytomX Therapeutics, Inc. Q2 FY2024 Earnings Call
Confident tone
CX-904 EGFR-CD3 PROBODY T-cell Engager
CX-2051 EpCAM PROBODY ADC
Amgen partnership and Phase 1b strategy
Revenue
$25.11M
▲ 1.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
CytomX Therapeutics, Inc. Q1 FY2024 Earnings Call
Confident tone
CX-904 Phase Ia dose escalation data
Safety profile and therapeutic window
Dose optimization and step dosing strategy
Revenue
$41.46M
▲ 76.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-11
CytomX Therapeutics, Inc. Q4 FY2023 Earnings Call
Positive tone
CX-904 EGFRxCD3 Probody T-cell engager
Upcoming pipeline milestones / catalysts
CX-2051 EpCAM Probody ADC
Revenue
$26.61M*
▲ 32.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
CytomX Therapeutics, Inc. Q3 FY2023 Earnings Call
Revenue
$26.38M
▲ 136.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
CytomX Therapeutics, Inc. Q2 FY2023 Earnings Call
Revenue
$24.72M
▲ 92.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
CytomX Therapeutics, Inc. Q1 FY2023 Earnings Call
Revenue
$23.50M
▲ 159.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-27
CytomX Therapeutics, Inc. Q4 FY2022 Earnings Call
Revenue
$20.12M*
▲ 80.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
CytomX Therapeutics, Inc. Q3 FY2022 Earnings Call
Revenue
$11.15M
▼ 36.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
CytomX Therapeutics, Inc. Q2 FY2022 Earnings Call
Revenue
$12.85M
▼ 21.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
CytomX Therapeutics, Inc. Q1 FY2022 Earnings Call
Revenue
$9.04M
▼ 43.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
CytomX Therapeutics, Inc. Q4 FY2021 Earnings Call
Revenue
$11.13M
▲ 57.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
CytomX Therapeutics, Inc. Q3 FY2021 Earnings Call
Revenue
$17.59M
▼ 1.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
CytomX Therapeutics, Inc. Q2 FY2021 Earnings Call
Revenue
$16.29M
▼ 1.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
CytomX Therapeutics, Inc. Q1 FY2021 Earnings Call
Revenue
$15.97M
▼ 67.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-19
CytomX Therapeutics, Inc. Q4 FY2020 Earnings Call
Revenue
$7.08M
▼ 14.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
CytomX Therapeutics, Inc. Q3 FY2020 Earnings Call
Revenue
$17.79M
▲ 66.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
CytomX Therapeutics, Inc. Q2 FY2020 Earnings Call
Revenue
$16.61M
▲ 84.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
CytomX Therapeutics, Inc. Q1 FY2020 Earnings Call
Revenue
$49.59M
▲ 68.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-27
CytomX Therapeutics, Inc. Q4 FY2019 Earnings Call
Revenue
$8.28M
▼ 27.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–29 of 29 earnings calls
Key facts
CIK
1501989
CUSIP
23284F105
13F (30d)
182 filings
176 filers
Visit website
Investor relations